Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

• Status: Not yet recruiting
• Trial end date: 2027-10-01

Summary

This phase I trial studies the side effects and best dose of loncastuximab tesirine in combination with carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy regimen in treating patients with diffuse large B-cell lymphoma that has come back (recurrent) or has not responded to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with loncastuximab tesirine may kill more cancer cells.

• Phase: Phase 1

Details

• Lead Sponsor: Fred Hutchinson Cancer Research Center
• Collaborator: ADC Therapeutics
• Treatments: Carmustine; Cytarabine; Etoposide; Etoposide phosphate; Loncastuximab tesirine; Mechlorethamine; Melphalan; Nitrogen Mustard Compounds; Podophyllotoxin